ONC and Revolution Medicines Forge Key Deal: Exclusive RAS(ON) Inhibitor Rights in Asia and Combination Trials Shape Future Oncology Roadmap
Market Chameleon (Mon, 10-Aug 7:08 AM)
BeOne Medicines Raises 2026 Revenue Guidance After Brukinsa’s Strong Global Growth and Pipeline Advancements
Market Chameleon (Wed, 5-Aug 7:39 AM)
BRUKINSA Plus Rituximab Shown to Reduce Risk of Progression or Death by 43% in Frontline Mantle Cell Lymphoma—Chemotherapy-Free Regimen Meets Key Phase 3 Endpoint
Market Chameleon (Tue, 30-Jun 7:09 AM)
